Physician profile
Varun Bavyer
NPI 1134482623
$2,732.60
in general payments reported to CMS, 2019-2025
22 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.53 · 2020: $29.73 · 2021: $270 · 2022: $445 · 2023: $324 · 2024: $1,248 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Long Term Medical Supply Or Device Loan: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.04 |
| Long Term Medical Supply Or Device Loan | $898.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eko Health, INC. | $898.00 | 2024 | |
| Merck Sharp & Dohme LLC | $425.51 | 2021-2025 | Verquvo |
| Amgen INC. | $191.25 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $167.46 | 2021-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.21 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.67 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $144.44 | 2021-2022 | |
| Bridgebio Pharma, INC. | $93.38 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $81.55 | 2023-2024 | Xarelto |
| Pfizer INC. | $55.10 | 2021-2025 | |
| Amarin Pharma, INC. | $50.93 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.90 | 2020-2022 | |
| Boston Scientific Corporation | $47.15 | 2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $40.57 | 2022-2023 | Eliquis |
| Medicomp INC | $34.37 | 2024 | Telepatch Cardiac Monitor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.64 | 2022 | |
| Organogenesis INC. | $21.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.72 | 2025 | |
| Genzyme Corporation | $18.48 | 2023 | |
| Acist Medical Systems, INC. | $15.82 | 2019 | |
| Cashflow Solutions, LLC | $15.22 | 2024 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Irhythm Technologies, INC. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Bavyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.